Condition: SARS-CoV-2 · Sponsor: ModernaTX, Inc.
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
This description comes directly from the study's public registry record.
Moderna WeCare Team · 1-866-663-3762 · WeCareClinicalTrials@modernatx.com
Always discuss trial participation with your own doctor first.
| CenExel | Atlanta, Georgia, United States | Recruiting |
| CenExel | Decatur, Georgia, United States | Recruiting |
| Velocity Clinical Research | Baton Rouge, Louisiana, United States | Recruiting |
| Velocity Clinical Research | Gulfport, Mississippi, United States | Recruiting |
| Velocity Clinical Research | Omaha, Nebraska, United States | Recruiting |
| Richard Bennett - Clinical Research Partners | Richmond, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06585241